• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

靶向化疗药物引起的皮肤不良反应：一项临床流行病学研究

Cutaneous Adverse Drug Reactions to Targeted Chemotherapeutic Drugs: A Clinico-Epidemiological Study.

作者信息

Saini Kriteeka, Sutaria Amita, Shah Bela, Brahmbhatt Vinita, Parmar Kirti

机构信息

Department of Dermatology, B.J. Medical College and Civil Hospital, Ahmedabad, Gujarat, India.

出版信息

Indian J Dermatol. 2019 Nov-Dec;64(6):471-475. doi: 10.4103/ijd.IJD_491_18.

DOI:10.4103/ijd.IJD_491_18
PMID:31896846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6862361/
Abstract

BACKGROUND

Targeted chemotherapeutic drugs have led to a remarkable improvement in the survival of cancer patients but also have resulted in the increased incidence of uncommon but specific muco-cutaneous adverse effects.

AIMS

This study aimed to highlight the spectrum of such cutaneous adverse drug reactions and to derive a causal association.

MATERIALS AND METHODS

A hospital-based, descriptive study was carried out in the dermatology outpatient department between August 2016 and July 2018, on patients referred from the state cancer institute, who developed muco-cutaneous lesions after the initiation of targeted chemotherapeutic drugs.

RESULTS

A total of 80 patients, 59 (74%) males and 21 (26%) females of mean age 45.83 ± 16.37 years (range 4-70 years) developed one or more uncommon albeit specific muco-cutaneous adverse effects. Among them, papulopustular and acneiform eruptions were found in 21 patients (26.25%), and PRIDE complex was seen in 3 patients. Sixteen patients (20.00%) developed palmar-plantar erythrodysesthesia, 8 patients (10%) developed lichenoid drug eruption, and 5 patients (6.25%) developed flagellate dermatitis. Twenty-two (27.5%) patients showed nail changes, the most common, being melanonychia.

CONCLUSION

There has been a paradigm shift in the management of both hematopoietic and solid cancers with the advent of targeted chemotherapeutic drugs leading to an increase in uncommon and specific drug reactions. Early recognition of these decreases morbidity, improves quality of life, and allows continuation of the life saving chemotherapy.

摘要

背景

靶向化疗药物显著提高了癌症患者的生存率，但也导致了罕见但特定的黏膜皮肤不良反应的发生率增加。

目的

本研究旨在突出此类皮肤药物不良反应的范围，并得出因果关系。

材料与方法

2016年8月至2018年7月，在皮肤科门诊对从国家癌症研究所转诊的患者进行了一项基于医院的描述性研究，这些患者在开始使用靶向化疗药物后出现了黏膜皮肤病变。

结果

共有80例患者，其中59例（74%）为男性，21例（26%）为女性，平均年龄45.83±16.37岁（范围4 - 70岁），出现了一种或多种罕见但特定的黏膜皮肤不良反应。其中，21例患者（26.25%）出现丘疹脓疱性和痤疮样皮疹，3例患者出现PRIDE综合征。16例患者（20.00%）出现掌跖红细胞感觉异常，8例患者（10%）出现苔藓样药疹，5例患者（6.25%）出现鞭毛虫皮炎。22例（27.5%）患者出现指甲改变，最常见的是甲下黑素沉着。

结论

随着靶向化疗药物的出现，造血系统癌症和实体癌的治疗模式发生了转变，导致罕见和特定药物反应增加。早期识别这些反应可降低发病率，提高生活质量，并允许继续进行挽救生命的化疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/907544f07757/IJD-64-471-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/9dd4852ce298/IJD-64-471-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/2c9860cf374b/IJD-64-471-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/cb39b24f26d8/IJD-64-471-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/49356ff7a7dd/IJD-64-471-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/ddba6d2b67ae/IJD-64-471-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/9987b25d0a64/IJD-64-471-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/6a17a6d03746/IJD-64-471-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/95443426fb4e/IJD-64-471-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/68e869f35dbe/IJD-64-471-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/8c36c8c1f33b/IJD-64-471-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/907544f07757/IJD-64-471-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/9dd4852ce298/IJD-64-471-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/2c9860cf374b/IJD-64-471-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/cb39b24f26d8/IJD-64-471-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/49356ff7a7dd/IJD-64-471-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/ddba6d2b67ae/IJD-64-471-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/9987b25d0a64/IJD-64-471-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/6a17a6d03746/IJD-64-471-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/95443426fb4e/IJD-64-471-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/68e869f35dbe/IJD-64-471-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/8c36c8c1f33b/IJD-64-471-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee40/6862361/907544f07757/IJD-64-471-g011.jpg

相似文献

1
Cutaneous Adverse Drug Reactions to Targeted Chemotherapeutic Drugs: A Clinico-Epidemiological Study.靶向化疗药物引起的皮肤不良反应：一项临床流行病学研究
Indian J Dermatol. 2019 Nov-Dec;64(6):471-475. doi: 10.4103/ijd.IJD_491_18.
2
Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study.癌症患者化疗的皮肤不良反应：一项临床流行病学研究。
Indian J Dermatol. 2018 Jan-Feb;63(1):41-46. doi: 10.4103/ijd.IJD_65_17.
3
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.靶向肿瘤治疗引起的丘疹脓疱性皮疹及其他皮肤副作用：一项回顾性研究
Cutan Ocul Toxicol. 2019 Sep;38(3):261-266. doi: 10.1080/15569527.2019.1594874. Epub 2019 May 7.
4
Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.癌症化疗药物和靶向治疗的皮肤反应：第二部分。靶向治疗。
J Am Acad Dermatol. 2014 Aug;71(2):217.e1-217.e11; quiz 227-8. doi: 10.1016/j.jaad.2014.04.013.
5
Clinical Profile of Patients with Lichenoid Drug Eruption: A Observational Study.苔藓样药疹患者的临床特征：一项观察性研究。
Indian J Dermatol. 2024 Mar-Apr;69(2):137-144. doi: 10.4103/ijd.ijd_878_23. Epub 2024 Apr 29.
6
Mucocutaneous Adverse Reactions of Cancer Chemotherapy and Chemoradiation.癌症化疗和放化疗的皮肤黏膜不良反应
Indian J Dermatol. 2019 Mar-Apr;64(2):122-128. doi: 10.4103/ijd.IJD_129_17.
7
Cutaneous adverse drug reaction profile in a tertiary care out patient setting in eastern India.印度东部一家三级护理门诊的药物不良反应皮肤表现。
Indian J Pharmacol. 2012 Nov-Dec;44(6):792-7. doi: 10.4103/0253-7613.103304.
8
Cutaneous reactions to chemotherapy and their management.化疗引起的皮肤反应及其处理
Am J Clin Dermatol. 2006;7(1):45-63. doi: 10.2165/00128071-200607010-00005.
9
Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study.接受抗癌药物治疗的门诊患者的皮肤不良事件与生活质量：一项观察性横断面研究的结果
Drugs Context. 2020 Aug 5;9. doi: 10.7573/dic.2020-6-6. eCollection 2020.
10
Clinical study of cutaneous drug eruptions in 200 patients.200例皮肤药物疹的临床研究
Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):430. doi: 10.4103/0378-6323.42883.

引用本文的文献

1
Mucocutaneous Findings in Hematolymphoid Neoplasms: An Observational Study.血液淋巴系统肿瘤的皮肤黏膜表现：一项观察性研究
Indian Dermatol Online J. 2023 Aug 29;14(5):630-636. doi: 10.4103/idoj.idoj_438_22. eCollection 2023 Sep-Oct.
2
Nail Whispers Revealing Dermatological and Systemic Secrets: An Analysis of Nail Disorders Associated With Diverse Dermatological and Systemic Conditions.指甲的低语：揭示皮肤病学和全身健康的秘密——对与各种皮肤病学和全身疾病相关的指甲疾病的分析
Cureus. 2023 Sep 11;15(9):e45007. doi: 10.7759/cureus.45007. eCollection 2023 Sep.

本文引用的文献

1
Dermatological adverse events with taxane chemotherapy.紫杉烷类化疗的皮肤不良事件。
Eur J Dermatol. 2016 Oct 1;26(5):427-443. doi: 10.1684/ejd.2016.2833.
2
Lichenoid drug eruption associated with Bendamustine.与苯达莫司汀相关的苔藓样药物疹。
Blood Cancer J. 2016 Jun 24;6(6):e438. doi: 10.1038/bcj.2016.48.
3
Dermatological adverse reactions to cancer chemotherapy.癌症化疗的皮肤不良反应
Indian J Dermatol Venereol Leprol. 2015 Jul-Aug;81(4):434. doi: 10.4103/0378-6323.159950.
4
Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.表皮生长因子受体和多激酶抑制剂的皮肤毒性
J Adv Pract Oncol. 2012 May;3(3):138-50. doi: 10.6004/jadpro.2012.3.3.2.
5
Imatinib mesylate-induced severe lichenoid rash.甲磺酸伊马替尼诱发的严重苔藓样皮疹。
Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):93-5. doi: 10.4103/0378-6323.125505.
6
Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation.鞭毛样皮炎作为细胞毒性药物治疗的博莱霉素特异性不良反应：临床-组织病理学相关性。
Am J Clin Dermatol. 2011 Feb 1;12(1):68-76. doi: 10.2165/11537080-000000000-00000.
7
Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.穿掘性毛囊炎、血管性水肿、手足综合征——索拉非尼治疗患者出现的多种皮肤副作用。
J Dtsch Dermatol Ges. 2009 May;7(5):449-52. doi: 10.1111/j.1610-0387.2009.07017.x. Epub 2009 Jan 29.
8
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.新型多激酶抑制剂索拉非尼皮肤不良反应的前瞻性研究。
Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886.
9
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.接受多激酶抑制剂索拉非尼和舒尼替尼治疗的癌症患者的手足皮肤反应。
Ann Oncol. 2008 Nov;19(11):1955-61. doi: 10.1093/annonc/mdn389. Epub 2008 Jun 10.
10
Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins.紫杉醇和曲妥珠单抗治疗引起的皮肤光敏性与卟啉生物合成异常有关。
J Dermatolog Treat. 2005 Feb;16(1):19-21. doi: 10.1080/09546630510026724.